Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Two-Period, Double-Blind Placebo-Controlled and Open-Label, Multicenter Extension Study to Determine the Long-Term Safety and Tolerability of JNJ-54861911 in Subjects in the Early Alzheimer's Disease Spectrum

NCT02406027 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.

NCT NCT02406027
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02406027 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Two-Period, Double-Blind Placebo-Controlled and Open-Label, Multicenter Extension Study to Determine the Long-Term Safety and Tolerability of JNJ-54861911 in Subjects in the Early Alzheimer's Disease Spectrum
Lead sponsor
Janssen Research & Development, LLC
Phase
Phase 2
Overall status
Terminated
Start date
July 2, 2015
Completion date
June 28, 2018
Enrollment
90 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease